Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (354)
SAGE documentation (33)
Scientific publications (4)
Systematic reviews (SYSVAC) (1089)
Regions
Africa (57)
Americas (187)
Eastern Mediterranean (10)
Europe (155)
South-East Asia (10)
Western Pacific (36)
Diseases
COVID-19 (1481)
Chikungunya (9)
Cholera (33)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (12)
Moderate (7)
Low (111)
Critically low (685)
Not applicable (274)
1481 results found
2022
∙
SAGE
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
2022
∙
SAGE
Good practice statement on the use of second booster doses for COVID-19 vaccines
2022
∙
SAGE
Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19
2022
∙
SAGE
Background document on the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2022
∙
SAGE
Annexes to the interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2022
∙
SAGE
Background document on the Valneva VLA2001 vaccine against COVID-19
2022
∙
SAGE
Annexes to the interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19
2022
∙
NACI
Recommendations on the use of bivalent Omicroncontaining mRNA COVID-19 vaccines
2022
∙
SAGE
Interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19
2022
∙
NIAC
NIAC Recommendations for additional COVID-19 Booster Vaccination
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register